Tozinameran

概览

Tozinameran is an mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus.

作用机制

Comirnaty contains nucleoside modified mRNA (modRNA) encapsulated in lipid nanoparticles that deliver the modRNA into host cells. The lipid nanoparticle formulation facilitates the delivery of the RNA into human cells. Once inside these cells, the modRNA is translated by host machinery to produce a modified SARS-CoV-2 spike (S) protein antigen, which is subsequently recognized by the host immune system. Comirnaty has been shown to elicit both neutralizing antibody and cellular immune responses to the S protein, which helps protect against subsequent SARS-CoV-2 infection.

适应症

Comirnaty is fully approved by the FDA and Health Canada for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged five years and older. A third booster shot is also approved by Health Canada for individuals five years and older and by the FDA for individuals 16 or older, to be given more than 6 months after their second immunization. The interchangeability of Comirnaty with COVID-19 vaccines from other manufacturers to complete the primary vaccination course or the booster dose (third dose) has not been established. Comirnaty is also approved for use as a fourth booster shot in adults 50 years of age and older. In the US, under the emergency use authorization, Comirnaty is used for the prevention of COVID-19 in children 6 months of age and older. Comirnaty is also available as an Omicron BA.4/BA.5 bivalent-adapted booster. This vaccine should only be administered where appropriate medical treatment for immediate allergic reactions are immediately available in the case of an acute anaphylactic reaction after vaccine administration. Comirnaty administration should be postponed in any individual suffering from an acute febrile illness. Immunocompromised individuals maybe have a weaker immune response to Comirnaty.

• Coronavirus Disease 2019 (COVID‑19)